Indo-Bangla Pharmaceuticals Ltd.
DDSE:IBP12.70
BDT
-0.10
(-0.78%)
Indo-Bangla Pharmaceuticals Ltd.
DSE:IBP
(Dhaka Stock Exchange)
Recent
price
12.70
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Indo-Bangla Pharmaceuticals Limited is a Bangladesh-based pharmaceutical manufacturing company engaged in the development, production, marketing, and commercial distribution of generic finished pharmaceutical formulations and healthcare products. Founded in 2014 and headquartered in Dhaka, Bangladesh, with its primary manufacturing facility situated in Barishal, the company operates across human healthcare and veterinary segments. The company's core product portfolio comprises diverse dosage forms and therapeutic classes, including solid dosage forms such as tablets and capsules; liquid preparations including oral syrups, suspensions, and pediatric drops; dry powder syrups for reconstitution; topical applications comprising ointments, creams, and medicated gels; and specialized veterinary formulations. Its pharmaceutical treatments span broad therapeutic segments, including antibiotics, antibacterials, and antifungals; analgesics, antipyretics, and anti-inflammatory medications; anti-ulcerants, gastrointestinal therapies, and antacids; antihistamines and respiratory relief medications; cardiovascular agents; and nutritional supplements, multivitamins, and hematinics. Indo-Bangla Pharmaceuticals distributes its products to retail pharmacies, healthcare institutions, hospitals, and clinics throughout Bangladesh while pursuing export initiatives in target international markets. In recent developments, the company has advanced strategic upgrades and capacity expansion programs at its Barishal manufacturing facility to enhance production volume and strengthen compliance with current Good Manufacturing Practice (cGMP) standards. Additionally, the company has broadened its commercial catalog with the introduction of new generic product formulations in acute and chronic therapeutic areas, optimized its nationwide distribution and supply network, and implemented operational and governance adjustments to support sustainable production and listing compliance on the Dhaka Stock Exchange and Chittagong Stock Exchange.